BETHPAGE CAPITAL CORP.

Condensed Consolidated Interim Financial Statements

March 31, 2019

Presented in Canadian dollars - unaudited

BETHPAGE CAPITAL CORP.

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by the entity's auditor.

BETHPAGE CAPITAL CORP.

Condensed Consolidated Interim Statements of Financial Position
(Presented in Canadian dollars - unaudited)

		March 31, 2019		December 31, 2018 (audited)
Assets				
Current assets				
Cash	$	1,237	$	2,658
Receivables (Note 3)		3,615		4,780
Total assets	$	4,852	$	7,438
Liabilities and equity				
Current liabilities				
Accounts payable and accrued liabilities (Note 4)	$	174,449	$	132,082
Loan (Note 5)		7,000		-
Total current liabilities		181,449		132,082
Equity				
Share capital (Note 6)		571,959		571,959
Reserves (Note 6)		154,780		154,780
Deficit		(903,336)		(851,383)
Total equity		(176,597)		(124,644)
Total liabilities and equity	$	4,852	$	7,438

Nature and continuance of operations (Note 1)

These condensed consolidated interim financial statements have been approved by the Board of directors and authorized for issue on May 30, 2019.

Ralph Olson, Director

Scott Reeves, Director

The accompanying notes are an integral part of these condensed interim financial statements

BETHPAGE CAPITAL CORP.
Condensed Consolidated Interim Statements of Comprehensive Loss
(Presented in Canadian dollars - unaudited)

	Three months ended March 31, 2019	Three months ended March 31, 2018
Expenses		
Accounting and audit	$ -	$ 1,650
Legal	43,585	-
Regulatory and listing fees	2,333	4,997
General and administrative	6,035	6,054
	(51,953)	(12,701)
Other items		
Interest income	-	43
Comprehensive loss	$ (51,953)	$ (12,658)
Basic and diluted loss per share	$ (0.01)	$ (0.00)
Weighted average number of shares outstanding (Notes 6)	4,450,000	4,450,000

The accompanying notes are an integral part of these condensed interim financial statements

BETHPAGE CAPITAL CORP.
Condensed Consolidated Interim Statement of Changes in Equity
(Presented in Canadian dollars - unaudited)

	Share capital		Reserves			
	Common shares	Amount	Stock- based compensation	Warrant	Deficit	Total equity
Balance, December 31, 2017	4,200,000	$ 571,020	$ 58,306	$ 96,474	$ (703,090)	$ 13,649
Comprehensive loss	–	–	–	–	(12,658)	(12,658)
Balance, March 31, 2018	4,450,000	571,959	58,306	96,474	(715,748)	10,991
Balance, December 31, 2018	4,200,000	$ 571,959	$ 58,306	$ 96,474	$ (851,383)	$ (124,644)
Comprehensive loss	–	–	–	–	(51,953)	(51,953)
Balance, March 31, 2019	**4,450,000**	**$ 571,959**	**$ 58,306**	**$ 96,474**	**$ (903,336)**	**$ (176,597)**

* The number of issued and outstanding shares has been adjusted to reflect the two for one share consolidation that was completed on May 30, 2019.

The accompanying notes are an integral part of these condensed interim financial statements

BETHPAGE CAPITAL CORP.
Condensed Consolidated Interim Statements of Cash Flows
(Presented in Canadian dollars - unaudited)

	Three months ended March 31, 2019	Three months ended March 31, 2018
Cash provided by (used in):		
Operating activities		
Net loss	$ (51,953)	$ (12,658)
Changes in non-cash working capital items:		
Receivables	1,165	(191)
Accounts payable and accrued liabilities	42,367	1,417
Net cash used in operating activities	(8,421)	(11,432)
Financing activities:		
Loan proceeds	7,000	-
Net cash from financing activities	7,000	-
Change in cash	(1,421)	(11,432)
Cash, beginning	2,658	34,522
Cash, ending	$ 1,237	$ 23,090

1. Nature and continuance of operations

Bethpage Capital Corp. (the “Company”) was incorporated pursuant to the Business Corporations Act of British Columbia on May 13, 2010. The Company is currently evaluating investment opportunities. The Company is domiciled in Canada and its office is at Suite 717 – 1030 West Georgia Street, Vancouver, BC.

Pursuant to a prospectus filed with the British Columbia and Alberta Securities Commissions, the Company completed an Initial Public Offering (“IPO”) on June 19, 2012 and its shares were listed for trading on the TSX Venture Exchange (the “Exchange”), as a Tier 2 issuer on June 21, 2012. On October 20, 2016 the Company’s listing transferred to the NEX Board of the Exchange under the symbol “BET.H”.

These condensed consolidated interim financial statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations. As at March 31, 2019, the Company had no sources of revenue and is not able to finance day to day activities through operations. As at March 31, 2019, the Company had a net working capital deficiency of $176,597 and an accumulated deficit of $903,336. The Company’s continuation as a going concern is dependent upon its ability to identify a suitable investment opportunity and raise equity capital or borrowings sufficient to meet current and future obligations. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern. Management intends to finance operating costs over the next twelve months with cash in hand, loans from directors and companies controlled by directors and or private placement of common shares. Should the Company be unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its statement of financial position.

The number of issued and outstanding shares has been adjusted to reflect the two for one share consolidation that was completed on May 30, 2019.

2. Significant accounting policies

(a) Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. The condensed consolidated interim financial statements do not include all of the information required of full annual financial statements and are intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. The condensed interim financial statements should be read in conjunction with the annual audited consolidated financial statements for the year ended December 31, 2018, which have been prepared in accordance with IFRS as issued by the IASB. However, these condensed consolidated interim financial statements provide selected significant disclosures that are required in the annual financial statements under IFRS.

(Presented in Canadian dollars - unaudited)

2. Significant accounting policies (continued)

(b) Basis of consolidation

The financial statements include the accounts of the Company and the wholly owned subsidiary 2173969 Alberta Ltd., incorporated on February 21, 2019. All inter-company transactions and balances with subsidiaries have been eliminated. All companies have the same reporting period.

(c) Use of estimates and judgments

The preparation of the Company's financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

Significant areas requiring the use of estimates include the fair value of stock-based compensation, and deferred income tax asset valuation allowance.

3. Receivables

	March 31, 2019	December 31, 2018
GST receivable	$ 3,615	$ 4,780

4. Accounts payable and accrued liabilities

	March 31, 2019	December 31, 2018
Trade accounts payable	$ 145,736	$ 122,082
Accrued liabilities	28,713	10,000
	$ 174,449	$ 132,082

5. Loan

On February 14, 2019, the Company received a non-interest bearing loan from Green Star Biosciences Inc. ("Green Star") in the amount of $7,000. The loan is unsecured and payable on demand.

The Company entered into an Amalgamation Agreement with Green Star dated effective February 28, 2019, pursuant to which the Company will acquire all of the issued and outstanding securities of Green Star in exchange for securities of the Company. The proposed transaction is expected to be carried out by way of a three-cornered amalgamation under the Business Corporations Act (British Columbia). Prior to the amalgamation, the Company will consolidate its common shares on a one for two basis.

Pursuant to the transaction, and following the consolidation, the issued and outstanding common shares of Green Star will be exchanged for common shares of the Company on a one-for-one basis.

(Presented in Canadian dollars - unaudited)

6. Share capital

(a) Common shares

Authorized: unlimited common shares without par value.

Issued: At March 31, 2019, there were 4,450,000 issued and fully paid common shares (December 31, 2018 – 4,450,000).

(b) Warrants

As at March 31, 2019 and December 31, 2018, the Company had no outstanding warrants.

(c) Stock options

On November 9, 2011, the Company adopted an incentive stock option plan, which provides that the Board of Directors of the Company may from time to time, at its discretion, and in accordance with the Exchange requirements, grant to directors, officers, key employees and consultants to the Company, options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the common shares issued an outstanding. Such options will be exercisable for a period of up to 10 years from the date of grant. In connection with the foregoing, the number of common shares reserved for issuance to any one optionee will not exceed five percent (5%) of the issued and outstanding common shares and the number of common shares reserved for issuance to all technical consultants will not exceed two percent (2%) of the issued and outstanding common shares. Options may be exercised no later than 90 days following cessation of the optionee's position with the Company or 30 days following cessation of an optionee conducting investor relations activities' position.

Stock option transactions are summarized as follows:

	Number of Options	Weighted Average Exercise Price
Outstanding at December 31, 2018 and March 31, 2019	112,500	$ 0.30

The weighted average contractual life of the options outstanding is 3.23 years.

The following table summarizes information about stock options outstanding and exercisable at March 31, 2019:

Number of Shares	Exercise Price	Expiry date	Exercisable
112,500	$0.30	June 21, 2022	112,500

6. Share capital (continued)

(d) Reserves

Stock-based compensation reserve

The stock-based compensation reserve records items recognized as stock-based compensation expense until such time that the stock options are exercised, at which time the corresponding amount will be transferred to share capital.

Warrant reserve

The warrant reserve records the value recorded for warrants issued until such time the warrants are exercised, at which time the corresponding amount will be transferred to share capital.

7. Related Party Transactions

There were no amounts paid to directors, officers or companies controlled by directors of the Company for the periods ended March 31, 2019 and 2018.

8. Financial instruments and risks

(a) Fair values

The fair values of cash, receivables and accounts payable approximate their carrying values due to the short-term to maturities of these financial instruments.

(b) Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as it does not have any assets or liabilities that are affected by changes in interest rates.

(c) Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is in its cash. The risk in cash is managed through the use of a major financial institution which has a high credit quality as determined by rating agencies. Credit risk is assessed as low.

(d) Foreign exchange rate risk

Foreign exchange risk is the risk that the Company's financial instruments will fluctuate in value as a result of movements in foreign exchange rates. The Company has no assets or liabilities denominated in foreign currencies; therefore, is not exposed to foreign exchange risk.

8. Financial instruments and risks (continued)

(e) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company requires funds to finance its business development activities. In addition, the Company needs to raise equity financing to carry out its exploration programs. There is no assurance that financing will be available or, if available, that such financings will be on terms acceptable to the Company. Liquidity risk is assessed as high.

(f) Price risk

The Company is exposed to price risk with respect to commodity prices. The Company's ability to raise capital to fund exploration and development activities is subject to risks associated with fluctuations in the market price of commodities. Price risk is assessed as low.

9. Capital management

The Company's capital structure consists of cash and share capital. The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company is dependent on external financing to fund its activities. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management since inception. The Company is not subject to externally imposed capital requirements.

10. Subsequent event

The Company entered into an Amalgamation Agreement dated effective February 28, 2019, pursuant to which the Company will acquire all of the issued and outstanding securities of Green Star Biosciences Inc. ("Green Star") in exchange for securities of the Company. The proposed transaction was carried out by way of a three-cornered amalgamation under the Business Corporations Act (British Columbia). Prior to completion of the amalgamation, the Company consolidated its common shares on a one for two basis. The transaction is subject to final acceptance of the Canadian Securities Exchange which is expected to be obtained next week.

For purposes of the transaction, the Company had registered a new, wholly-owned subsidiary company, 2173969 Alberta Ltd., incorporated on February 21, 2019.

Pursuant to the transaction, and following the consolidation, the issued and outstanding common shares of Green Star will be exchanged for common shares of the Company on a one-for-one basis. In connection with the transaction, the Company changed the name of the Company to GreenStar Biosciences Corp. On May 30, 2019, the Company completed the merger and immediately after the completion of the proposed transaction, the former shareholders of Green Star were issued 62,522,789 Bethpage Common Shares and assumed the obligations under the existing Green Star outstanding options and warrants.